AI-generated voice clones are bringing back the voices of people with MND, allowing some to communicate, connect, and even ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The Type ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Medicare Advantage plans are health insurance alternatives to Original Medicare, which provides health insurance to people ...

Roy and his wife, Jamie, asked Wake County to offer that lump sum to officers like him who medically retire but don’t ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in patients with amyotrophic lateral sclerosis. | Trouble sleeping is common in ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.